Chronic pre-treatment with memantine prevents amyloid-beta protein-mediated long-term potentiation disruption.
Citation:
Li F, Chen X, Wang F, Xu S, Chang L, Anwyl R, Wang Q, Chronic pre-treatment with memantine prevents amyloid-beta protein-mediated long-term potentiation disruption., Neural regeneration research, 8, 1, 2013, 49-55Download Item:
journal.pone.0052581.pdf (PDF) 399.3Kb
Abstract:
Previous studies indicate that memantine, a low-affinity N-methyl-D-aspartate receptor antagonist, exerted acute protective effects against amyloid-β protein-induced neurotoxicity. In the present study, the chronic effects and mechanisms of memantine were investigated further using electrophysiological methods. The results showed that 7-day intraperitoneal application of memantine, at doses of 5 mg/kg or 20 mg/kg, did not alter hippocampal long-term potentiation induction in rats, while 40 mg/kg memantine presented potent long-term potentiation inhibition. Then further in vitro studys were carried out in 5 mg/kg and 20 mg/kg memantine treated rats. We found that 20 mg/kg memantine attenuated the potent long-term potentiation inhibition caused by exposure to amyloid-β protein in the dentate gyrus in vitro. These findings are the first to demonstrate the antagonizing effect of long-term systematic treatment of memantine against amyloid-β protein triggered long-term potentiation inhibition to improve synaptic plasticity.
Author's Homepage:
http://people.tcd.ie/ranwylDescription:
PUBLISHED
Author: ANWYL, ROGER
Type of material:
Journal ArticleCollections:
Series/Report no:
Neural regeneration research8
1
Availability:
Full text availableKeywords:
PhysiologyDOI:
http://dx.doi.org/10.3969/j.issn.1673-5374.2013.01.006ISSN:
1673-5374Licences: